<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fanconi <z:hpo ids='HP_0001903'>anaemia</z:hpo> (FA) is a rare <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disease</z:e> characterized by <z:mp ids='MP_0008866'>chromosomal instability</z:mp>, somatic abnormalities, marrow failure and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> proness </plain></SENT>
<SENT sid="1" pm="."><plain>The main cause of morbidity and mortality is <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, which typically arises in the first decade of life and progresses to full-blown transfusion dependence and severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in a variable number of years </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may arise on the background of marrow failure, although cases of patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or overt <z:mpath ids='MPATH_336'>leukaemia</z:mpath> before the full appearance of marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> are reported </plain></SENT>
<SENT sid="3" pm="."><plain>This article reviews the current options for treatment of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> in FA and provides an algorithm for supporting decisions on treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The use of <z:chebi fb="5" ids="50113">androgens</z:chebi>, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and growth factors is reviewed, as well as the results in recent cohorts of matched sibling donor haematopoietic stem cell (<z:chebi fb="15" ids="50443">HSC</z:chebi>) transplants and unrelated donor <z:chebi fb="15" ids="50443">HSC</z:chebi> transplants, including cord blood graft </plain></SENT>
<SENT sid="5" pm="."><plain>The conditioning regimens used are analysed and commented </plain></SENT>
<SENT sid="6" pm="."><plain>Up-to-date information on second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> after <z:chebi fb="15" ids="50443">HSC</z:chebi> transplant and on experimental treatments such as gene therapy, prenatal and preimplantation diagnosis and inhibition of pro-inflammatory cytokines is provided </plain></SENT>
</text></document>